Do analysts recommend PULM or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, PULM or PLRZ?

Polyrizon has lower revenue, but higher earnings than Pulmatrix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmatrix $7.81M 0.75 -$5.16M -$1.10 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is PULM or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Pulmatrix's return on equity. Company Net Margins Return on Equity Return on Assets Pulmatrix N/A -125.65% -95.19% Polyrizon N/A N/A N/A

Do analysts prefer PULM or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PULM or BFRI more profitable?

Pulmatrix has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Pulmatrix's return on equity of -125.65% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Pulmatrix N/A -125.65% -95.19% Biofrontera -13.78% -145.81% -31.30%

Do analysts recommend PSTV or PULM?

Plus Therapeutics presently has a consensus target price of $51.75, indicating a potential upside of 1,648.31%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Pulmatrix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend PULM or CYCN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate LEXX or PULM?

Lexaria Bioscience presently has a consensus target price of $22.50, indicating a potential upside of 93.97%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Lexaria Bioscience is more favorable than Pulmatrix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LEXX or PULM more profitable?

Pulmatrix's return on equity of -125.65% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -174.93% -143.89% Pulmatrix N/A -125.65% -95.19%

Pulmatrix (PULM) Competitors

$1.60 +0.05 (+3.23%)

Closing price 08/25/2026 03:48 PM Eastern

Extended Trading

$1.59 -0.01 (-0.63%)

As of 08/25/2026 04:10 PM Eastern

Compare

PULM vs. PLRZ, BFRI, PSTV, CYCN, and LEXX

Should you buy Pulmatrix stock or one of its competitors? Pulmatrix's main competitors and comparable companies include Polyrizon (PLRZ), Biofrontera (BFRI), Plus Therapeutics (PSTV), Cyclerion Therapeutics (CYCN), and Lexaria Bioscience (LEXX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Pulmatrix compare to Polyrizon?

Pulmatrix (NASDAQ:PULM) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Pulmatrix has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.5, indicating that its share price is 250% less volatile than the broader market.

Polyrizon's return on equity of 0.00% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-125.65%	-95.19%
Polyrizon	N/A	N/A	N/A

Polyrizon has lower revenue, but higher earnings than Pulmatrix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.75	-$5.16M	-$1.10	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Polyrizon had 3 more articles in the media than Pulmatrix. MarketBeat recorded 5 mentions for Polyrizon and 2 mentions for Pulmatrix. Polyrizon's average media sentiment score of 0.66 beat Pulmatrix's score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulmatrix	Neutral
Polyrizon	Positive

11.8% of Pulmatrix shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Polyrizon beats Pulmatrix on 5 of the 9 factors compared between the two stocks.

How does Pulmatrix compare to Biofrontera?

Pulmatrix (NASDAQ:PULM) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by company insiders. Comparatively, 8.1% of Biofrontera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pulmatrix has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Pulmatrix's return on equity of -125.65% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-125.65%	-95.19%
Biofrontera	-13.78%	-145.81%	-31.30%

Pulmatrix has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pulmatrix has higher earnings, but lower revenue than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.75	-$5.16M	-$1.10	N/A
Biofrontera	$41.71M	0.54	-$10.54M	-$0.45	N/A

In the previous week, Biofrontera had 1 more articles in the media than Pulmatrix. MarketBeat recorded 3 mentions for Biofrontera and 2 mentions for Pulmatrix. Pulmatrix's average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.

Company	Overall Sentiment
Pulmatrix	Neutral
Biofrontera	Neutral

Summary

Pulmatrix and Biofrontera tied by winning 7 of the 14 factors compared between the two stocks.

How does Pulmatrix compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

Pulmatrix has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Pulmatrix's return on equity of -125.65% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Pulmatrix	N/A	-125.65%	-95.19%

Plus Therapeutics presently has a consensus target price of $51.75, indicating a potential upside of 1,648.31%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Pulmatrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pulmatrix has higher revenue and earnings than Plus Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Pulmatrix	$7.81M	0.75	-$5.16M	-$1.10	N/A

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Pulmatrix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Pulmatrix had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for Pulmatrix and 1 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 equaled Pulmatrix'saverage media sentiment score.

Company	Overall Sentiment
Plus Therapeutics	Neutral
Pulmatrix	Neutral

Summary

Pulmatrix beats Plus Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Pulmatrix compare to Cyclerion Therapeutics?

Pulmatrix (NASDAQ:PULM) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Cyclerion Therapeutics has lower revenue, but higher earnings than Pulmatrix. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.75	-$5.16M	-$1.10	N/A
Cyclerion Therapeutics	$2.07M	9.04	-$3.53M	-$1.66	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pulmatrix has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-125.65%	-95.19%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

In the previous week, Pulmatrix had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Pulmatrix and 1 mentions for Cyclerion Therapeutics. Pulmatrix's average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score.

Company	Overall Sentiment
Pulmatrix	Neutral
Cyclerion Therapeutics	Neutral

Pulmatrix has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 0.6% of Pulmatrix shares are held by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Pulmatrix and Cyclerion Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Pulmatrix compare to Lexaria Bioscience?

Lexaria Bioscience (NASDAQ:LEXX) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Lexaria Bioscience presently has a consensus target price of $22.50, indicating a potential upside of 93.97%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Lexaria Bioscience is more favorable than Pulmatrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pulmatrix's return on equity of -125.65% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Pulmatrix	N/A	-125.65%	-95.19%

13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pulmatrix has higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	26.96	-$11.90M	-$5.10	N/A
Pulmatrix	$7.81M	0.75	-$5.16M	-$1.10	N/A

In the previous week, Lexaria Bioscience and Lexaria Bioscience both had 2 articles in the media. Lexaria Bioscience's average media sentiment score of 0.00 equaled Pulmatrix'saverage media sentiment score.

Company	Overall Sentiment
Lexaria Bioscience	Neutral
Pulmatrix	Neutral

Lexaria Bioscience has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

Summary

Pulmatrix beats Lexaria Bioscience on 7 of the 13 factors compared between the two stocks.

Get Pulmatrix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PULM vs. The Competition

Export

Metric	Pulmatrix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.66M	$12.52B	$7.34B	$12.72B
Dividend Yield	N/A	2.61%	2.53%	10.79%
P/E Ratio	-1.45	778.15	271.01	24.15
Price / Sales	0.75	753.37	630.63	102.20
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	3.64	12.01	13.02	6.25
Net Income	-$5.16M	$2.80B	$3.46B	$347.86M
7 Day Performance	5.26%	2.87%	1.53%	0.98%
1 Month Performance	-3.03%	6.54%	8.82%	5.24%
1 Year Performance	-67.21%	8.04%	26.07%	17.04%

Pulmatrix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PULM Pulmatrix	0.5094 of 5 stars	$1.60 +3.2%	N/A	-67.8%	$5.66M	$7.81M	N/A	20	Short Interest Decrease Gap Down
PLRZ Polyrizon	1.0047 of 5 stars	$11.19 +8.0%	N/A	+78.1%	$21.59M	N/A	N/A	N/A	Short Interest Increase Gap Down
BFRI Biofrontera	1.1139 of 5 stars	$1.42 -1.4%	N/A	+63.8%	$21.39M	$41.71M	N/A	70	Short Interest Decrease
PSTV Plus Therapeutics	2.0473 of 5 stars	$3.08 -3.8%	$51.75 +1,580.2%	-75.6%	$21.20M	N/A	N/A	20
CYCN Cyclerion Therapeutics	0.6151 of 5 stars	$4.13 +0.2%	N/A	+56.9%	$19.29M	$2.07M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PULM) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmatrix (PULM) Competitors

PULM vs. PLRZ, BFRI, PSTV, CYCN, and LEXX

How does Pulmatrix compare to Polyrizon?

Summary

How does Pulmatrix compare to Biofrontera?

Summary

How does Pulmatrix compare to Plus Therapeutics?

Summary

How does Pulmatrix compare to Cyclerion Therapeutics?

Summary

How does Pulmatrix compare to Lexaria Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PULM vs. The Competition

Pulmatrix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulmatrix (PULM) Competitors

PULM vs. PLRZ, BFRI, PSTV, CYCN, and LEXX

How does Pulmatrix compare to Polyrizon?

Which has more volatility and risk, PULM or PLRZ?

Is PULM or PLRZ more profitable?

Which has preferable earnings and valuation, PULM or PLRZ?

Do analysts recommend PULM or PLRZ?

Does the media favor PULM or PLRZ?

Do insiders and institutionals have more ownership in PULM or PLRZ?

Summary

How does Pulmatrix compare to Biofrontera?

Do institutionals and insiders hold more shares of PULM or BFRI?

Is PULM or BFRI more profitable?

Which has more risk & volatility, PULM or BFRI?

Do analysts prefer PULM or BFRI?

Which has higher earnings & valuation, PULM or BFRI?

Does the media favor PULM or BFRI?

Summary

How does Pulmatrix compare to Plus Therapeutics?

Which has more risk and volatility, PSTV or PULM?

Is PSTV or PULM more profitable?

Do analysts recommend PSTV or PULM?

Which has higher earnings & valuation, PSTV or PULM?

Do insiders & institutionals have more ownership in PSTV or PULM?

Does the media refer more to PSTV or PULM?

Summary

How does Pulmatrix compare to Cyclerion Therapeutics?

Which has better earnings & valuation, PULM or CYCN?

Do analysts recommend PULM or CYCN?

Is PULM or CYCN more profitable?

Does the media favor PULM or CYCN?

Which has more volatility and risk, PULM or CYCN?

Do insiders and institutionals have more ownership in PULM or CYCN?

Summary

How does Pulmatrix compare to Lexaria Bioscience?

Do analysts rate LEXX or PULM?

Is LEXX or PULM more profitable?

Do institutionals and insiders have more ownership in LEXX or PULM?

Which has better valuation & earnings, LEXX or PULM?

Does the media refer more to LEXX or PULM?

Which has more risk & volatility, LEXX or PULM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PULM vs. The Competition

Pulmatrix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools